Detailed view for Tb927.3.5090

Basic information

TDR Targets ID: 20626
Trypanosoma brucei, tryparedoxin 2, putative
Source Database / ID:  TriTrypDB  GeneDB

pI: 6.0837 | Length (AA): 198 | MW (Da): 22180 | Paralog Number: 2

Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 1

Druggability Group : DG1

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF13905   Thioredoxin-like

Gene Ontology

Mouse over links to read term descriptions.
GO:0016491   oxidoreductase activity  
GO:0016209   antioxidant activity  
GO:0045454   cell redox homeostasis  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 3 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
17 170 1o8x (A) 11 145 38.00 0 1 1.22788 -1.25
19 58 4hqz (A) 54 91 45.00 0.32 0.68 0.52132 1.26
37 79 1jfu (A) 61 102 40.00 0.41 0.87 0.632472 0.29

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 80-100% percentile Procyclic, Bloodstream Form. Siegel TN
Show/Hide expression data references
  • Siegel TN Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites.

Orthologs

Ortholog group members (OG5_128012)

Species Accession Gene Product
Arabidopsis thaliana AT1G60420   protein reduce transmission through pollen
Babesia bovis BBOV_II002190   hypothetical protein
Brugia malayi Bm1_46700   thioredoxin
Brugia malayi Bm1_18575   NXN protein
Brugia malayi Bm1_46705   thioredoxin, identical
Caenorhabditis elegans CELE_F29B9.5   Protein F29B9.5
Caenorhabditis elegans CELE_R05H5.3   Protein R05H5.3
Caenorhabditis elegans CELE_K02H11.6   Protein TRX-5
Caenorhabditis elegans CELE_T20D4.7   Protein T20D4.7
Caenorhabditis elegans CELE_C32D5.8   Protein C32D5.8, isoform A
Homo sapiens ENSG00000130045   nucleoredoxin-like 2
Homo sapiens ENSG00000167693   nucleoredoxin
Leishmania braziliensis LbrM.29.1230   tryparedoxin
Leishmania braziliensis LbrM.31.2190   tryparedoxin-like protein
Leishmania braziliensis LbrM.29.1220   tryparedoxin
Leishmania donovani LdBPK_291240.1   tryparedoxin 2, putative
Leishmania donovani LdBPK_291250.1   tryparedoxin 1, putative
Leishmania donovani LdBPK_312000.1   tryparedoxin 3, putative
Leishmania infantum LinJ.29.1240   tryparedoxin
Leishmania infantum LinJ.29.1250   tryparedoxin
Leishmania infantum LinJ.31.2000   tryparedoxin-like protein
Leishmania major LmjF.29.1160   tryparedoxin
Leishmania major LmjF.31.1970   tryparedoxin-like protein
Leishmania major LmjF.31.1960   tryparedoxin-like protein
Leishmania major LmjF.29.1150   tryparedoxin
Leishmania mexicana LmxM.08_29.1160   tryparedoxin
Leishmania mexicana LmxM.30.1960   tryparedoxin-like protein
Leishmania mexicana LmxM.30.1970   tryparedoxin-like protein
Leishmania mexicana LmxM.08_29.1150   tryparedoxin, putative
Loa Loa (eye worm) LOAG_12576   hypothetical protein
Loa Loa (eye worm) LOAG_14349   hypothetical protein
Loa Loa (eye worm) LOAG_10373   hypothetical protein
Loa Loa (eye worm) LOAG_16265   hypothetical protein
Loa Loa (eye worm) LOAG_15500   NXN protein
Mus musculus ENSMUSG00000021396   nucleoredoxin-like 2
Mus musculus ENSMUSG00000020844   nucleoredoxin
Neospora caninum NCLIV_055730   hypothetical protein
Neospora caninum NCLIV_047650   nnucleoredoxin, putative
Oryza sativa 4333075   Os03g0405500
Oryza sativa 4333077   Os03g0405900
Onchocerca volvulus OVOC9602   Nucleoredoxin homolog
Schmidtea mediterranea mk4.000223.01  
Trypanosoma brucei gambiense Tbg972.3.4110   tryparedoxin
Trypanosoma brucei gambiense Tbg972.3.4070   tryparedoxin
Trypanosoma brucei gambiense Tbg972.3.5720   tryparedoxin, putative
Trypanosoma brucei Tb927.3.5090   tryparedoxin 2, putative
Trypanosoma brucei Tb927.3.3760   tryparedoxin 1b, putative
Trypanosoma brucei Tb927.3.3780   tryparedoxin 1a, putative
Trypanosoma congolense TcIL3000_0_52740   tryparedoxin 1, putative
Trypanosoma congolense TcIL3000_0_54590   tryparedoxin 2, putative
Trypanosoma cruzi TcCLB.509997.20   tryparedoxin 2, putative
Trypanosoma cruzi TcCLB.509997.30   tryparedoxin 1, putative
Toxoplasma gondii TGME49_225060   nucleoredoxin family protein
Toxoplasma gondii TGME49_312110   apicoplast-associated thioredoxin family protein Atrx1

Essentiality

Tb927.3.5090 has direct evidence of essentiality
Gene/Ortholog Organism Phenotype Source Study
Tb927.3.3760 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb927.3.3760 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (6 days) alsford
Tb927.3.3760 Trypanosoma brucei no significant loss or gain of fitness in procyclic forms alsford
Tb927.3.3760 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
Tb927.3.5090 this record Trypanosoma brucei significant gain of fitness in bloodstream forms (3 days) alsford
Tb927.3.5090 this record Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (6 days) alsford
Tb927.3.5090 this record Trypanosoma brucei significant loss of fitness in procyclic forms alsford
Tb927.3.5090 this record Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
CELE_R05H5.3 Caenorhabditis elegans embryonic lethal wormbase
CELE_C32D5.8 Caenorhabditis elegans embryonic lethal wormbase
CELE_F29B9.5 Caenorhabditis elegans embryonic lethal wormbase
CELE_F29B9.5 Caenorhabditis elegans larval arrest wormbase
TGME49_312110 Toxoplasma gondii Essentiality uncertain sidik
TGME49_225060 Toxoplasma gondii Essentiality uncertain sidik
TGME49_312110 Toxoplasma gondii Probably essential sidik
TGME49_225060 Toxoplasma gondii Probably essential sidik
Show/Hide essentiality data references
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection

Phenotypes and Validation (curated)

Annotated phenotypes:

Affected Entity Phenotypic quality Occurs in Occurs at Evidence Observed in Drugs/Inhibitors
cell proliferation (GO:0008283) increased (PATO:0000470) bloodstream stage trypomastigotes (PLO:0027) inferred from RNAi experiment (ECO:0000019) No drug identifiers listed for this gene.
Annotator: fernan@iib.unsam.edu.ar. Comment: increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 3 days). References: 21363968
cell proliferation (GO:0008283) normal (PATO:0000461) bloodstream stage trypomastigotes (PLO:0027) inferred from RNAi experiment (ECO:0000019) No drug identifiers listed for this gene.
Annotator: fernan@iib.unsam.edu.ar. Comment: normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 6 days). References: 21363968
cell proliferation (GO:0008283) decreased (PATO:0000468) procyclic (PLO:0034) inferred from RNAi experiment (ECO:0000019) No drug identifiers listed for this gene.
Annotator: fernan@iib.unsam.edu.ar. Comment: decreased cell proliferation (significant loss of fitness) in procyclic forms . References: 21363968
cell proliferation (GO:0008283) normal (PATO:0000461) procyclic (PLO:0034) inferred from RNAi experiment (ECO:0000019) No drug identifiers listed for this gene.
Annotator: fernan@iib.unsam.edu.ar. Comment: normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . References: 21363968

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model
No druggable targets predicted through repurposing network model

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier Tb927.3.5090 (Trypanosoma brucei), tryparedoxin 2, putative
Title for this comment
Comment